HUTCHMED (NASDAQ:HCM) Stock Price Up 6.6% – Here’s What Happened

Posted by on Jul 2nd, 2026

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM – Get Free Report)’s share price traded up 6.6% during trading on Thursday . The stock traded as high as $11.64 and last traded at $11.4960. Approximately 48,063 shares changed hands during trading, an increase of 16% from the average daily volume of 41,289 shares. The stock had previously closed at $10.78.

Wall Street Analysts Forecast Growth

HCM has been the topic of several recent research reports. Weiss Ratings downgraded shares of HUTCHMED from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday. Bank of America decreased their target price on shares of HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, March 10th. Wall Street Zen lowered shares of HUTCHMED from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Morgan Stanley set a $13.60 price target on HUTCHMED in a report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $16.80.

Get Our Latest Report on HCM

HUTCHMED Stock Up 5.9%

The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05. The company has a 50 day moving average price of $11.83 and a 200-day moving average price of $13.59.

Hedge Funds Weigh In On HUTCHMED

A number of institutional investors and hedge funds have recently bought and sold shares of HCM. XY Capital Ltd raised its position in shares of HUTCHMED by 291.1% during the 3rd quarter. XY Capital Ltd now owns 52,757 shares of the company’s stock worth $831,000 after buying an additional 39,266 shares in the last quarter. UBS Group AG lifted its stake in shares of HUTCHMED by 112.8% in the 3rd quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after acquiring an additional 72,614 shares during the period. M&G PLC boosted its holdings in shares of HUTCHMED by 26.7% in the fourth quarter. M&G PLC now owns 259,033 shares of the company’s stock valued at $3,367,000 after acquiring an additional 54,601 shares in the last quarter. Amundi boosted its holdings in shares of HUTCHMED by 41.9% in the third quarter. Amundi now owns 223,330 shares of the company’s stock valued at $3,620,000 after acquiring an additional 65,898 shares in the last quarter. Finally, State Street Corp increased its stake in shares of HUTCHMED by 1.2% during the fourth quarter. State Street Corp now owns 321,305 shares of the company’s stock valued at $4,283,000 after acquiring an additional 3,801 shares during the period. Institutional investors own 8.82% of the company’s stock.

About HUTCHMED

(Get Free Report)

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.

Featured Articles

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.